InDex Pharmaceuticals AB and CEO Peter Zerhouni presents at Redeye ABLife Science day the 11th. of November 2021 at 9 am.

InDex Pharmaceuticals AB is a development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate #cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals AB has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases